Translating Discoveries of Glial Biology & Peripheral Immune Pathways into Novel Approaches to Target Neuroinflammation Across the Neurodegenerative Disease Spectrum
Neuroimmunology is entering a defining moment. With Sanofi’s brain-penetrant BTK inhibitor advancing through regulatory review for neuroinflammation in MS, new clinical data demonstrating reversal of neuroinflammatory markers with oral NLRP3 inhibition in Parkinson’s disease, and growing mechanistic insight into TYK2 as a central neuroimmune modulator, the field is building momentum in both translational science and therapeutic innovation.
Now the real race begins: uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today’s successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease.
The 8th Neuroimmunology Drug Development Summit is the industry’s only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year’s expanded program goes deeper than ever into emerging glial biology (TREM2 & beyond), peripheral immune pathways, and the technologies redefining how we discover, validate, and measure neuroinflammatory targets.
Across three days, 50+ discovery, preclinical, and translational leaders from Biogen, Sanofi, Merck, Lundbeck, Vigil Neuroscience, Bristol Myers Squibb and more will unite to share insights on merging neuroinflammatory mechanisms, cutting-edge glial models and omics technologies accelerating target discovery, next-generation biomarkers enhancing translation, and early clinical signals from novel neuroimmune-targeting therapies.
Join the global neuroimmunology community this year and help define the future of immune-modulating therapies for the brain.
Speaker Spotlight Alert!
We're delighted to announce that Manuela Polydoro, Head of Translational Medicine, Muna Therapeutics will be joining the workshop day on ‘Workshop B: Advancing Biomarker Discovery in Neuroinflammatory Disease’.
The workshop will examine current strategies for identifying and validating biomarkers in neuroimmunology, the limitations of relying solely on RNA or protein based readouts, the role of patient samples, biobanks and computational approaches.
Want to see who else is speaking and what’s on the agenda? Checkout the Event Guide here.
Recently Booked On Companies
Attending Companies Include